In this article, we will look at the 8 Hidden Multibagger Stocks to Buy Now.
Finding multibagger stocks, i.e., stocks that grow to many times their original value, is the ultimate goal of many investors. Achieving this is never easy, as many investors jump ship too early in a stock’s journey, assuming all future prospects are already priced in. In this way, while the stock’s prospects are clear to everyone, they remain hidden under the profit-taking pressure, prompting investors to avoid adding them to their portfolios.
JP Morgan, in its mid-year outlook 2026 report, stated that despite the market trading at an elevated valuation, this is still the right time to add to your holdings:
Crucially, the near-term conditions seem to present a compelling opportunity for long-term investors to add to their equity market holdings.
Continuing to buy outperforming stocks is one way to invest in multibaggers, and, with JPMorgan believing the time is right to stay invested, it may be prudent to continue this strategy.
To discover these opportunities in the market, we look at companies that have already given decent returns in the last year. The near-term headwinds caused by geopolitical uncertainties and inflation fears often generate opportunities in the same stocks as they continue their journey higher. We therefore decided to compile our own list of hidden multibagger stocks to buy now.
Our Methodology
To come up with our list of 8 hidden multibagger stocks to buy now, we looked at stocks with a market cap of at least $2 billion that had returned at least 50% over the last year. Investors often ignore these companies because they believe their future potential is already priced in. However, quite often, the same stocks continue performing, turning into multibaggers. We therefore included only companies that analysts believe still have at least 50% upside from here. These stocks have recently reported investor-worthy news and are arranged in ascending order of potential upside, according to Wall Street analysts.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Note: All share price data is as of market close on June 30, 2026.
8. Resideo Technologies Inc. (NYSE:REZI)
Potential Upside: 65.5%
On July 1, Jay Goldberg from Seaport Research started coverage of Resideo Technologies Inc. (NYSE:REZI) with a Buy rating and set a price target of $55. The firm’s assigned price target reflects an additional 76% upside from current levels. Despite weakness in the consumer electronics market, the firm believes two key developments will support the company’s growth. First is the renegotiated agreement with its parent company, which is expected to generate $140 million in additional annual cash flow. Second, Resideo is preparing to spin off its lower-margin distribution business. According to the analyst, the company’s security and safety products are generally more resilient than other consumer products and tend to perform well even during slower housing markets.
For fiscal year 2026, Resideo Technologies Inc. (NYSE:REZI) reaffirmed its outlook and provided ranges for the second quarter. The company expects total company net revenue for the quarter to range from $1.916 billion to $1.940 billion. Total adjusted EBITDA is projected to range between $216 million and $230 million. On the earnings side, fully diluted EPS is forecasted to be in the range of $0.71 to $0.75.
CFO Michael Carlet remarked:
We anticipate higher costs during 2026 in areas such as fuel on freight. We intend to take pricing actions starting in the second quarter that are intended to fully mitigate these increasing costs. There could be a slight headwind to the gross margin for each business segment in the second quarter.
Resideo Technologies Inc. (NYSE:REZI) makes smart home technology for comfort, energy management, and safety, including thermostats (Honeywell Home), smoke detectors, security systems, and water management, and also operates ADI Global Distribution, a major wholesale distributor of security, fire, and low-voltage products to professionals worldwide.
7. Kinross Gold Corporation (NYSE:KGC)
Potential Upside: 78.4%
On June 30, UBS analyst Daniel Major lowered the firm’s price target on Kinross Gold Corporation (NYSE:KGC) from $38 to $30 and maintained a Buy rating. The firm’s downward-adjusted price target suggests an additional 27% upside from here on. This upside is equal to the lowest Wall Street analysts’ upside estimate, based on 21 analysts covering the stock. Moreover, the median Wall Street price target of $41.88 implies a further 78% upside from current levels.
In addition to UBS, RBC Capital shared similar sentiments on June 3. The firm cut its price target on the stock from $45 to $40 while keeping a Buy rating. However, its revised price target is still attractive to investors as compared to that of UBS.
On a bullish note, Bank of America Securities shared a positive stance towards the stock earlier on May 30. The firm raised its price target on Kinross Gold Corporation (NYSE:KGC) from $43.50 to $46.00 while reaffirming a Buy rating on the shares. The firm’s revised price target reflects an impressive 95% upside from here on. This upside is slightly higher than the median Wall Street analysts’ upside.
Based in Canada, Kinross Gold Corporation (NYSE:KGC) is involved in the production, exploration, acquisition, and development of gold properties. Its operations are divided into the following business segments: Tasiast, Paracatu, La Coipa, Fort Knox, Round Mountain, Bald Mountain, and Corporate & Other.
6. Vera Therapeutics Inc. (NASDAQ:VERA)
Potential Upside: 92.2%
On June 11, Wells Fargo reiterated its Buy rating on Vera Therapeutics Inc. (NASDAQ:VERA) stock, along with a price target of $70.
Earlier on June 2, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics Inc. (NASDAQ:VERA) and set a target price of $90 on the stock. The positive analyst sentiment is driven by the strong potential of the company’s lead drug candidate, atacicept, for treating IgA nephropathy. The company’s agreement with the FDA, announced on June 2, 2026, allows VERA to analyze key kidney function data from its Phase III ORIGIN 3 study earlier than expected. Moreover, if the trial results are positive, the firm could apply for full FDA approval of its lead drug, atacicept, in the fourth quarter of 2026.
In addition, the analyst also pointed to strong data from an earlier Phase IIb eGFR study and noted atacicept is currently under priority review for accelerated approval. The drug may be approved for a broader group of IgA nephropathy patients, which could expand its market opportunity, noted the analyst.
Vera Therapeutics Inc. (NASDAQ:VERA) is a clinical-stage biotechnology company. It focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company was formerly known as Trucode Gene Repair Inc. and changed its name to Vera Therapeutics Inc. in April 2020. It was incorporated in 2016 and is headquartered in Brisbane, California.
While we acknowledge the potential of VERA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VERA and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Hidden Multibagger Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
